NeuraLight Named One of TIME’s World’s Top HealthTech Companies 2026

Recognition reflects NeuraLight’s accelerating momentum, breakthrough clinical progress, and expanding impact across the brain health ecosystem

NEW YORK & TEL AVIV, Israel — NeuraLight, a leader in precision brain function biomarkers, today has been named one of TIME’s World’s Top HealthTech Companies 2026.

The recognition comes at a period of significant clinical and commercial momentum for NeuraLight. Its precision brain function platform is expanding across pharmaceutical development, large-scale longitudinal studies, longevity, and broader brain health, advancing the company’s vision to make brain function measurable with the precision needed to transform how brain health is understood, treated, and managed.

Over the past year, NeuraLight has accelerated its expansion across these areas, with growing adoption spanning pharmaceutical partners including Mission Therapeutics and Kariya, where NeuraLight is supporting the development of next-generation GLP-1 therapies for neuroprotection, alongside population-scale initiatives such as HeBA, a multinational healthy brain ageing study.

“From the beginning, our vision has been to make brain function measurable with a level of precision that can fundamentally change how we understand and manage brain health,” said Edmund Ben-Ami, CEO and Co-Founder of NeuraLight. “Seeing NeuraLight recognized by TIME is an important milestone, but what matters most is seeing that vision move into practice across a growing number of programs.”

NeuraLight was recognized alongside companies including Tempus AI, ŌURA, and Prenuvo, reflecting a broader shift toward more precise, data-driven approaches to measuring health.

‍